BROADWOOD CAPITAL INC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 110 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.

Quarter-by-quarter ownership
BROADWOOD CAPITAL INC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$41,223,872
-16.3%
34,935,4850.0%3.66%
-0.5%
Q2 2023$49,259,034
-6.0%
34,935,4850.0%3.68%
-0.1%
Q1 2023$52,403,228
+28.2%
34,935,4850.0%3.69%
+7.8%
Q4 2022$40,874,517
+3.5%
34,935,4850.0%3.42%
+13.5%
Q3 2022$39,477,000
-28.5%
34,935,4850.0%3.01%
-27.6%
Q2 2022$55,198,000
+2.6%
34,935,4850.0%4.16%
+7.3%
Q1 2022$53,801,000
-35.4%
34,935,485
+2.7%
3.88%
-24.2%
Q4 2021$83,313,000
-2.8%
34,005,3790.0%5.12%
+17.1%
Q3 2021$85,694,000
-11.6%
34,005,3790.0%4.37%
+0.9%
Q2 2021$96,915,000
+21.3%
34,005,3790.0%4.33%
+2.0%
Q1 2021$79,913,000
+33.5%
34,005,3790.0%4.25%
+19.7%
Q4 2020$59,849,000
+87.9%
34,005,3790.0%3.55%
+41.8%
Q3 2020$31,849,000
+7.7%
34,005,3790.0%2.50%
+8.3%
Q2 2020$29,585,000
+5.1%
34,005,3790.0%2.31%
-29.7%
Q1 2020$28,160,000
-7.0%
34,005,3790.0%3.29%
-5.7%
Q4 2019$30,265,000
-9.2%
34,005,3790.0%3.49%
-24.6%
Q3 2019$33,325,00034,005,3794.63%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2022
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders